{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bronchiectasis/prescribing-information/azithromycin/","result":{"pageContext":{"chapter":{"id":"6db0266e-4d15-5eec-b2c0-ed20f472eeb5","slug":"azithromycin","fullItemName":"Azithromycin","depth":2,"htmlHeader":"<!-- begin field 3ade7162-8ce5-4302-a6ea-abaa009a5016 --><h2>Azithromycin</h2><!-- end field 3ade7162-8ce5-4302-a6ea-abaa009a5016 -->","summary":"","htmlStringContent":"<!-- begin item 59e7d73f-6af2-4de2-b6f1-abaa009a4f88 --><!-- end item 59e7d73f-6af2-4de2-b6f1-abaa009a4f88 -->","topic":{"id":"96a8622b-46f5-55fa-b729-6748e3d98c98","topicId":"26fab339-e333-44ec-a481-de87a29052f3","topicName":"Bronchiectasis","slug":"bronchiectasis","lastRevised":"Last revised in January 2021","chapters":[{"id":"43d88c30-f768-5e1c-a6ea-5596c5577fb5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ac4fde9a-5fd3-5ed9-9201-f714bda470bb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0b34af83-d49a-5145-8589-e8748b8646c0","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"04eeb1ae-4fc3-5418-83a2-b62587d8bdda","slug":"changes","fullItemName":"Changes"},{"id":"dbd8ad5a-871c-59b8-9729-444e11ac9df1","slug":"update","fullItemName":"Update"}]},{"id":"b89644c6-805f-50b4-991d-36bb2b0fbf67","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d38de329-73b8-5fed-83ef-f836b765cd3f","slug":"goals","fullItemName":"Goals"},{"id":"3c116665-5586-5551-909c-0efc1ef0be62","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"60e13bc0-e351-5c39-b8ff-9a8d4514bf16","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2ee37cc0-9ff4-5bbd-ab3f-0a30cb904bb5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d155aa4f-7dfe-575d-a7dd-a87774f4cbad","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"07c3e24b-c950-516e-9070-5441a07b3791","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5146c866-f0a7-54a6-a5ac-8aff4b385cc6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e2107a7e-b7c3-5ba9-94e4-6217ea79a3f2","slug":"definition","fullItemName":"Definition"},{"id":"39df7c47-de08-57ae-aa40-89a7d4d7b031","slug":"causes","fullItemName":"Causes"},{"id":"ac4d346e-97d4-5d84-a704-fbdcf56be7f4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e07a8b0b-866c-5789-85ef-020a5b19b620","slug":"prognosis-complications","fullItemName":"Prognosis and complications"}]},{"id":"ef5c5e7b-3cf4-5939-85e0-b61cae41f945","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ce267b5b-70dd-52bd-ad83-6123bd42fa0d","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c605c0b9-0519-50e1-abd8-2dc47de7278a","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"23a1627d-30f7-5ba4-95f8-060faf797f51","slug":"suspected-infective-exacerbation-diagnosis","fullItemName":"Suspected infective exacerbation diagnosis"}]},{"id":"5a5846fa-c8b4-5cd4-b2d3-770c3dc00ba2","fullItemName":"Management","slug":"management","subChapters":[{"id":"0180d43c-dd8d-5a87-915c-629542f782fe","slug":"suspected-bronchiectasis","fullItemName":"Scenario: Suspected bronchiectasis"},{"id":"290c51ae-6521-5c03-b12e-117e40c88883","slug":"infective-exacerbation","fullItemName":"Scenario: Infective exacerbation"},{"id":"1e90ec28-8eea-5ab7-ac76-2df1ace279de","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ba1a593e-f80b-5c5f-be50-5979b491bc70","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6db0266e-4d15-5eec-b2c0-ed20f472eeb5","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"a98b5813-5589-5247-9c65-e9ae534d88c2","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"04c99c8f-7a1d-55f0-85a2-6d0e1bc3e4e3","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"26b521e3-9c5e-5a7c-956b-7f3f39f2e58c","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"6cd6079a-be84-5279-9d10-e3bf4653c049","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"8ed4a900-3e69-51c0-8cd5-c2b0bee9bfe2","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"5217d027-064d-5543-93b0-7e8bb1a1c0fc","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"cf1fbf18-e60a-54f7-bbc4-2a30ab37f565","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"8e888abe-cb05-5343-b6e3-547dea7312cc","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"}]},{"id":"118b4e08-e6ae-510a-b2f5-51b109ef3395","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ecf8de37-d8f0-5ced-af38-9be20fa73de9","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1c227675-02ea-5c9e-a927-e385987adf53","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f74bbe64-1998-528f-b811-df2a14219de7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2a925d45-6865-5cd5-9624-23da53ee221a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a6ff3076-9be6-55b4-b373-f40cb3045f2c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67608f46-5eba-58f9-86e3-0e0e3f57d921","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3fae7f8d-20fb-5fe6-af57-64882afceb3a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ba1a593e-f80b-5c5f-be50-5979b491bc70","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"065d29db-090a-5340-9e65-409ee5f817ea","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field a6560f19-6e54-4be1-a76d-abaa009a8f2e --><h3>What contraindications and cautions are associated with azithromycin?</h3><!-- end field a6560f19-6e54-4be1-a76d-abaa009a8f2e -->","summary":"","htmlStringContent":"<!-- begin item cf260409-8387-4c94-a218-abaa009a8efe --><!-- begin field 3e6fa89d-4fac-4b69-8766-abaa009a8f2e --><ul><li><strong>Prescribe azithromycin with caution in people:</strong><ul><li>Who may be predisposed to prolongation of the QT interval. For example, people with:<ul><li>Congenital or documented acquired QT prolongation.</li><li>Currently receiving treatment with other active substances known to prolong the QT interval, such as antiarrhythmics of classes IA and III.</li><li>With electrolyte disturbance, particularly in cases of hypokalaemia and hypomagnesaemia.</li><li>With clinically relevant bradycardia, cardiac arrhythmia, or severe cardiac insufficiency, including torsades de pointes.</li></ul></li><li>With severe hepatic impairment.</li><li>With severe renal impairment.</li><li>With myasthenia gravis — macrolides may aggravate symptoms.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 3e6fa89d-4fac-4b69-8766-abaa009a8f2e --><!-- end item cf260409-8387-4c94-a218-abaa009a8efe -->","subChapters":[]},{"id":"7f65ec8f-3aaf-5361-9fa7-19ac6e6dc391","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field ad1a0367-3d68-4738-8a64-abaa009a9f5b --><h3>What are the adverse effects of azithromycin?</h3><!-- end field ad1a0367-3d68-4738-8a64-abaa009a9f5b -->","summary":"","htmlStringContent":"<!-- begin item 27747f08-6cf9-447b-aea5-abaa009a9f34 --><!-- begin field c3ed7161-4b64-48b8-be0a-abaa009a9f5b --><ul><li><strong>Gastrointestinal </strong>— diarrhoea (very common), vomiting, abdominal pain, nausea (common).<ul><li>Rarely: pancreatitis, pseudomembranous colitis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Nervous system </strong>— headache (common), dizziness, somnolence, dysgeusia, paraesthesia (uncommon).<ul><li>Rarely: convulsions, hyperactivity, syncope, myasthenia gravis.</li></ul></li><li><strong>Psychiatric</strong> — nervousness, insomnia (uncommon).<ul><li>Rarely or very rarely: agitation, aggression, anxiety, delirium, hallucination.</li></ul></li><li><strong>Skin and subcutaneous tissue</strong> — rash, pruritus, urticaria, dermatitis (uncommon).<ul><li>Rarely, or very rarely: drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens–Johnson syndrome, toxic epidermal necrolysis, erythema multiforme.</li></ul></li><li><strong>Other adverse effects reported rarely, or very rarely, include: </strong><ul><li>Anaphylaxis.</li><li>Arrhythmias.</li><li>Arthralgia.</li><li>Hearing impairment.</li><li>Hepatitis, cholestatic jaundice.</li><li>Oedema.</li><li>Pancreatitis. </li><li>QT interval prolongation.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field c3ed7161-4b64-48b8-be0a-abaa009a9f5b --><!-- end item 27747f08-6cf9-447b-aea5-abaa009a9f34 -->","subChapters":[]},{"id":"dba0fca0-9a82-5fb1-bb2a-b204c38f1e50","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 164860c9-54d2-4750-bb7b-abaa009aad1a --><h3>What drug interactions are important with azithromycin?</h3><!-- end field 164860c9-54d2-4750-bb7b-abaa009aad1a -->","summary":"","htmlStringContent":"<!-- begin item 175cfe4d-7dd4-4121-8387-abaa009aacf3 --><!-- begin field 3b9b7f48-c1ea-4a38-a675-abaa009aad1a --><ul><li><strong>Antacids </strong>— plasma concentrations of azithromycin may be reduced. Simultaneous administration should be avoided — azithromycin should be taken at least 2 hours before, or 1 hour after antacids.</li><li><strong>Ciclosporin</strong> — azithromycin may increase cyclosporin levels. </li><li><strong>Cisapride </strong>— macrolides increase levels of cisapride, increasing the risk of arrhythmias (torsades de pointes). Concurrent use is contraindicated.</li><li><strong>Colchicine</strong> — azithromycin slightly increases the levels of colchicine. Stop or reduce the dose of colchicine. Avoid concomitant use in renal or hepatic impairment.</li><li><strong>Digoxin</strong> — cases of increased digoxin levels have been reported. Monitor for signs of digoxin adverse effects (such as bradycardia). Monitor and reduce the digoxin dose if required.</li><li><strong>Edoxaban </strong>— levels may be increased by azithromycin. Dose adjustment of edoxaban may be required.</li><li><strong>Rifabutin</strong> — azithromycin increases the risk of neutropenia when given with rifabutin. Monitor closely.</li><li><strong>Statins </strong>— there is a possible increased risk of myopathy.<ul><li>Advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Typhoid vaccine </strong>— antibacterials might reduce the immune response. The World Health Organization (WHO) recommends that the antibacterial is stopped from 3 days before to 3 days after receiving live oral typhoid vaccine.</li><li><strong>Warfarin</strong> — concurrent use may increase the international normalized ratio (INR). Consider increasing INR monitoring as this interaction appears to develop over the first 7 days.</li><li><strong>Drugs that prolong the QT interval</strong> (such as amiodarone, sotalol, and hydroxyzine) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended. If concurrent use is unavoidable consider ECG (electrocardiogram) monitoring.<ul><li>Concurrent use with domperidone, hydroxyzine, or mizolastine is contraindicated.</li></ul></li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, and short-acting beta-2 agonists) — hypokalaemia is a risk factor for QT prolongation.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Preston, 2020</a>]</p><!-- end field 3b9b7f48-c1ea-4a38-a675-abaa009aad1a --><!-- end item 175cfe4d-7dd4-4121-8387-abaa009aacf3 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}